title: Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus.
abstract: Posttransplantation diabetes mellitus (PTDM) is a common complication of kidney transplantation, associated with poorer graft and patient outcomes. Tacrolimus is a strong immunosuppressive drug associated with low acute rejection rates, but a higher risk for PTDM. High trough levels of tacrolimus during the first month after transplantation have been found to be a significant risk factor for the development of PTDM. The aim of this single-center study was to identify the risk factors for the development of PTDM among kidney transplant recipients under tacrolimus therapy. We examined 73 cadaveric kidney transplant recipients receiving tacrolimus between 1994 and 2003. Age, donor and recipient gender, dialysis method, body mass index (BMI), first year weight gain, mismatches, incidence of acute rejection and delayed graft function, hepatitis C serology, first year cumulative steroid dose, first tacrolimus blood level, first tacrolimus blood level <15 ng/mL, and corresponding tacrolimus daily doses and concentration/dose ratios (CDR) were also collected. PTDM was defined as at least 2 fasting blood glucose values > or =126 mg/dL, according to the World Health Organization criteria. Incidence of first year PTDM was 27.4%. Patients with PTDM showed significantly higher age, BMI, first tacrolimus blood level, first tacrolimus CDR, and CDR with tacrolimus blood level <15 ng/mL as well as less 1-year weight gain. After logistic regression, age (relative risk [RR] 1.060, confidence interval [CI] 95%, 1.001-1.122; P = .043) and first tacrolimus blood level (RR 1.154; CI 95%, 1.038-1.283; P = .008) remain significant risk factors for developing PTDM. Older age and initial tacrolimus blood levels were the main risk factors for PTDM among our group of patients. Kidney transplant recipients who develop PTDM maintain a high CDR of tacrolimus.
authors.affiliation: Service of Nephrology, Hospital Valdecilla, University of Cantabria, Santander, Spain. nefrce@humv.es
authors.forename: E
authors.initials: E
authors.lastname: Rodrigo
authors.forename: M A
authors.initials: MA
authors.lastname: de Cos
authors.forename: G
authors.initials: G
authors.lastname: Fernández-Fresnedo
authors.forename: B
authors.initials: B
authors.lastname: Sánchez
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
authors.forename: C
authors.initials: C
authors.lastname: Piñera
authors.forename: R
authors.initials: R
authors.lastname: Palomar
authors.forename: J G
authors.initials: JG
authors.lastname: Cotorruelo
authors.forename: C
authors.initials: C
authors.lastname: Gómez-Alamillo
authors.forename: S Sanz
authors.initials: SS
authors.lastname: de Castro
authors.forename: A L M
authors.initials: AL
authors.lastname: de Francisco
authors.forename: M
authors.initials: M
authors.lastname: Arias
mesh_terms: D000328:Adult; D015992:Body Mass Index; D003920:Diabetes Mellitus / Q000453:epidemiology*; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D012189:Retrospective Studies; D016559:Tacrolimus / Q000097:blood*; D014019:Tissue Donors; D015430:Weight Gain
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus